Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich’s ataxia (FA), emphasizing ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported first quarter 2026 financial results ...
IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results